I'd be eager to learn more, but it seems that they have only published the topline figures [1] and some of their methodology [2]. Details will follow in a journal.
Perhaps worth noting that development cost account for more than the phase 2-3 studies and that cost are lower for combinations of known drugs. But yes, 34 million is a lot less than 3 billion.
[1] https://msfaccess.org/precedent-setting-move-towards-drug-de...
> *Total costs were €33.9 million. While the topline results were presented at the WHO PPRI conference, the full detailed costs of the clinical trial have been submitted for a peer-review publication to a journal. In the full publication, the costs are broken down into 27 cost categories, by year, and by trial site, in order to offer a high level of transparency.
[2] https://msfaccess.org/transparency-core-clinical-trial-cost-...
replies(2):